These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 16465142)
1. Nanomedicine lacks recognition in Europe. Moran N Nat Biotechnol; 2006 Feb; 24(2):121. PubMed ID: 16465142 [No Abstract] [Full Text] [Related]
2. The science-business tango. Interview by Mari Paul. Hirth P Nat Biotechnol; 2006 Aug; 24(8):1035-6. PubMed ID: 16900153 [No Abstract] [Full Text] [Related]
3. Bio-Vision 2016: the second national framework plan for biotechnology promotion in Korea. Hyeon BH; Kim HY; Lee CM; Moon SH; Kim ES; Lee SY Biotechnol J; 2008 May; 3(5):591-600. PubMed ID: 18446865 [No Abstract] [Full Text] [Related]
4. University spin-offs: opportunity or challenge? Peng X Nat Mater; 2006 Dec; 5(12):923-5. PubMed ID: 17139301 [No Abstract] [Full Text] [Related]
9. Cenamps: adding value to the North East region. Maw A; Pitkethly M; Gohir S; McMurray A; Robbins D Nanomedicine (Lond); 2006 Dec; 1(4):499-504. PubMed ID: 17716155 [TBL] [Abstract][Full Text] [Related]
10. GlaxoSmithKline pushes its labs towards 'biotech' future. Adam D Nature; 2001 Mar; 410(6824):5. PubMed ID: 11242002 [No Abstract] [Full Text] [Related]
11. Demise of the life science company begins. Niiler E Nat Biotechnol; 2000 Jan; 18(1):14. PubMed ID: 10625374 [No Abstract] [Full Text] [Related]
12. Decentralization key to ScanBalt. Frank P Nat Biotechnol; 2005 Oct; 23(10):1211. PubMed ID: 16211052 [No Abstract] [Full Text] [Related]
13. The Canadian Regenerative Medicine and Nanomedicine Enterprise (CARMENE). Fenniri H Int J Nanomedicine; 2006; 1(3):225-7. PubMed ID: 17717963 [No Abstract] [Full Text] [Related]
14. Paths to entrepreneurship in the life sciences. Mehta S Nat Biotechnol; 2004 Dec; 22(12):1609-12. PubMed ID: 15605429 [No Abstract] [Full Text] [Related]
18. Merck hires top academic geneticist. Nowak R Science; 1994 Oct; 266(5185):538. PubMed ID: 7939697 [No Abstract] [Full Text] [Related]
19. The biotechnology sector's craving for commercial expertise is fuelling a cultural exchange with drug industry. Smaglik P; Frantz S Nature; 2003 Apr; 422(6931):542-3. PubMed ID: 12673255 [No Abstract] [Full Text] [Related]
20. In-process testing and limits. Sjöholm I Dev Biol Stand; 1997; 91():73-8. PubMed ID: 9413685 [No Abstract] [Full Text] [Related] [Next] [New Search]